Search research articles
Contact Us
Filters
Showing results (21-30 of 53) with videos related to
Page
of 6
Sort By:
Therapeutic Drug Monitoring
|
February 1, 1997
Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: evaluation of a paired approach for psychotropic medication
M Gex-Fabry, A E Balant-Gorgia, L P Balant
Therapeutic Drug Monitoring
|
February 1, 1995
Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide
M Gex-Fabry, A E Balant-Gorgia, L P Balant
Clinical Pharmacokinetics
|
June 1, 1991
Clinical pharmacokinetics of clomipramine
A E Balant-Gorgia, M Gex-Fabry, L P Balant
Therapeutic Drug Monitoring
|
March 2, 1999
Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors
A E Balant-Gorgia, M Gex-Fabry, C Genet, et al.
L'Encephale
|
April 25, 2006
[Validation of the QFS measuring the frequency and satisfaction in social behaviours in psychiatric adult population]
A Zanello, B Weber Rouget, M Gex-Fabry, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
April 1, 1987
Stereoselective disposition of flupentixol: influence on steady-state plasma concentrations in schizophrenic patients
A E Balant-Gorgia, L P Balant, M Gex-Fabry, et al.
Therapeutic Drug Monitoring
|
April 1, 1992
Persistent impairment of clomipramine demethylation in recently detoxified alcoholic patients
A E Balant-Gorgia, M Gay, M Gex-Fabry, et al.
Nordic Journal of Psychiatry
|
April 26, 2006
Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states
P Bech, M Gex-Fabry, J-M Aubry, et al.
Clinical Pharmacokinetics
|
September 1, 1990
Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data
M Gex-Fabry, A E Balant-Gorgia, L P Balant, et al.
Therapeutic Drug Monitoring
|
April 1, 1994
Clomipramine therapy in the geriatric hospital: experience with therapeutic drug monitoring
J P Bocksberger, M Gex-Fabry, L Gauthey, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 53) with videos related to
Sort By:
Page
of 6
Therapeutic Drug Monitoring
|
February 1, 1997
Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions: evaluation of a paired approach for psychotropic medication
M Gex-Fabry, A E Balant-Gorgia, L P Balant
Therapeutic Drug Monitoring
|
February 1, 1995
Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide
M Gex-Fabry, A E Balant-Gorgia, L P Balant
Clinical Pharmacokinetics
|
June 1, 1991
Clinical pharmacokinetics of clomipramine
A E Balant-Gorgia, M Gex-Fabry, L P Balant
Therapeutic Drug Monitoring
|
March 2, 1999
Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors
A E Balant-Gorgia, M Gex-Fabry, C Genet, et al.
L'Encephale
|
April 25, 2006
[Validation of the QFS measuring the frequency and satisfaction in social behaviours in psychiatric adult population]
A Zanello, B Weber Rouget, M Gex-Fabry, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
April 1, 1987
Stereoselective disposition of flupentixol: influence on steady-state plasma concentrations in schizophrenic patients
A E Balant-Gorgia, L P Balant, M Gex-Fabry, et al.
Therapeutic Drug Monitoring
|
April 1, 1992
Persistent impairment of clomipramine demethylation in recently detoxified alcoholic patients
A E Balant-Gorgia, M Gay, M Gex-Fabry, et al.
Nordic Journal of Psychiatry
|
April 26, 2006
Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states
P Bech, M Gex-Fabry, J-M Aubry, et al.
Clinical Pharmacokinetics
|
September 1, 1990
Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data
M Gex-Fabry, A E Balant-Gorgia, L P Balant, et al.
Therapeutic Drug Monitoring
|
April 1, 1994
Clomipramine therapy in the geriatric hospital: experience with therapeutic drug monitoring
J P Bocksberger, M Gex-Fabry, L Gauthey, et al.
Page
of 6